Background {#Sec1}
==========

Renal cancer accounts for 2% to 3% of all cancers, and the rate of renal cell carcinoma (RCC) has increased by 1.6% per year for the past 10 years \[[@CR1]\]. Approximately 90% of renal cancer is RCC, and surgery is the only curative treatment. About 20% of RCC patients have advanced stage disease, and for those with localized RCC, nearly 30% show recurrence after tumor resection \[[@CR2], [@CR3]\]. Therefore, we need better prognostic models to improve prognosis.

The TNM stage, reflecting tumor invasion, lymph node metastasis and distant metastasis, is the most widely used system for predicting RCC prognosis \[[@CR2]\]. However, because of heterogeneous prognoses, the outcomes of some patients with the same stage of cancer may be completely different. Therefore, we need useful biomarkers to increase the prognostic accuracy in RCC.

Increasing evidence supports that inflammation and nutrition are involved in the initiation and progression of various cancers, including RCC \[[@CR4]\]. Hematologic parameters including albumin and hemoglobin levels and lymphocytes, neutrophils and platelets counts are easily acquired laboratory data reflecting inflammation and nutrition status and have been extensively studied. Numerous studies have reported the prognostic value of serum albumin and hemoglobin levels and lymphocyte and platelet counts for various cancers, including RCC \[[@CR5]--[@CR8]\]. However, the disadvantage of these indicators is that each reflects only one respect of inflammation or nutrition. Further studies found that the combination of those factors in an index such as the prognostic nutritional index (PNI), combining albumin level and lymphocyte count, or the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR) or platelet-to-lymphocyte ratio (PLR) could more accurately predict prognosis than a single index \[[@CR9]--[@CR12]\].

A novel index combining hemoglobin and albumin levels and lymphocyte and platelet counts (HALP) has been found significantly associated with outcomes in colorectal and gastric cancer \[[@CR13], [@CR14]\]. In this study, we investigated the clinical value of this index in RCC patients undergoing nephrectomy.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

We included 1360 patients with histologically confirmed RCC. All patients were underwent nephrectomy in the Department of Urology, Peking University First Hospital, between 2001 and 2010. Clinicopathologic characteristics and laboratory data were collected. Follow-up care including abdominal ultrasonography or abdominal CT, chest X-ray, and laboratory tests was performed at regular intervals (3-month intervals in years 1 to 3, 6-month intervals in years 4 to 5, and 12-month intervals in years 6 to 10 after diagnosis).

Statistical analysis {#Sec4}
--------------------

Data are presented as number (percentage) for categorical variables and median (interquartile range \[IQR\]) for continuous variables. HALP was calculated as hemoglobin level (g/L) × albumin level (g/L) × lymphocyte(/L)/platelet count (/L), NLR as neutrophil-to-lymphocyte count and PLR as platelet-to-lymphocyte count. The cut-off values for NLR, PLR and HALP were determined by using X-tile v3.6.1 (Yale University) \[[@CR15]\]. The X-tile software was able to compare the *P* values of different cut-off values for a continuous variable and determine the best cut-off value with the most significant P value. Chi-square test was used to analyze an association of clinicopathologic data with HALP. The Kaplan-Meier survival method was used to estimate cancer-specific survival (CSS), with log-rank test used to test significant differences. The significant variables in the univariate analysis were included in the Cox proportional-hazards regression multivariate survival analyses by Forward LR method. Statistical analyses involved use of SPSS v22.0 (SPSS Inc., Chicago, IL, USA) and *P* \< 0.05 was considered statistically significant.

Results {#Sec5}
=======

Patient characteristics {#Sec6}
-----------------------

We included 1360 patients (952 men, median age 55 years \[IQR 46--65\]) (Table [1](#Tab1){ref-type="table"}). The median follow-up was 67 months (IQR 36--74) and 139 (10.2%) patients died due to RCC during follow-up. The 5-year estimated CSS was 89.4% for all patients.Table 1Basline clinicopathologic characteristics of 1360 patients with renal cell carcinoma (RCC) undergoing nephrectomyCharacteristicsTotal *n* = 1360Age, years, median (IQR)55 (46--65)Female sex408 (30%)Histology subtype ccRCC1228 (90.29%) non-ccRCC132 (9.71%)Location left626 (46.03%) right697 (51.25%) bilateral37 (2.72%)Fuhrman grade 1374 (27.5%) 2738 (54.26%) 3237 (17.43%) 411 (0.81%)T-stage 11015 (74.63%) 2113 (8.32%) 3225 (16.54%) 47 (0.51%)N status negative1327 (97.57%) positive33 (2.43%)ASA grade 1192 (14.12%) 21072 (78.82%) 3&496 (7.06%)Sarcomatoid transformation65 (4.78%)Metastasis61 (4.48%)Lymphovascular invasion100 (7.35%)Necrosis419 (3.08%)Hypoalbuminemia53 (3.9%)Anemia267 (19.6%)NLR, median (IQR)2.13 (1.60--2.85)PLR, median (IQR)124.07 (97.33--165.22)HALP, median (IQR)47.48 (33.21--63.45)Data are n (%) unless indicated. *IQR* interquartile ratio, *ccRCC* clear-cell renal cell carcinoma, *ASA* American Society of Anesthesiologists, *NLR* neutrophil-to-lymphocyte ratio, *PLR* platelet-to-lymphocyte ratio, *HALP* hemoglobin and albumin levels and lymphocyte and platelet counts

Association of HALP and clinicopathologic features {#Sec7}
--------------------------------------------------

We detected cut-off values for HALP, 31.2; NLR, 2.9; and PLR, 198.3 (Fig. [1](#Fig1){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Figure S1) for dividing patients into low and high HALP, NLR and PLR groups. Decreased HALP level was associated with being female, older age, high Fuhrman grade and high T stage and N and M positive status, sarcomatoid transformation, tumor necrosis, lymphovascular invasion and low NLR or PLR (Table [2](#Tab2){ref-type="table"}).Fig. 1Cut off value for hemoglobin and albumin levels and lymphocyte and platelet counts (HALP) by using X-tileTable 2Association of baseline clinicopathologic characteristics and HALPVariable*n* (%)HALP^a^low (%)high (%)*P* valueAll patients1360291 (21.40%)1069 (78.60%)Gender\< 0.001 male952 (70.00%)162 (17.02%)790 (82.98%) female408 (30.00%)129 (31.62%)279 (68.38%)Age, years\< 0.001  ≤ 65997 (73.31%)186 (18.66%)811 (81.34%) \>65363 (26.69%)105 (28.93%)258 (71.07%)Histology subtype0.695 ccRCC1228 (90.29%)261 (21.25%)967 (78.75%) non-ccRCC132 (9.71%)30 (22.73%)102 (77.27%)ASA grade0.361 1 + 21264 (92.94%)268 (21.20%)996 (78.80%) 3 + 496 (7.06%)23 (23.96%)68 (76.04%)Fuhrman grade\< 0.001 1 + 21112 (81.76%)177 (15.92%)935 (84.08%) 3 + 4248 (18.24%)113 (45.56%)130 (54.44%)T stage\< 0.001 1 + 21128 (82.94%)173 (15.34%)955 (84.66%) 3 + 4232 (17.06%)118 (50.86%)113 (49.14%)N status\< 0.001 negative1327 (97.57%)270 (20.35%)1057 (79.65%) positive33 (2.43%)21 (63.64%)12 (36.36%)Metastasis\< 0.001 negative1299 (95.51%)258 (19.86%)1041 (80.14%) positive61 (4.49%)33 (54.10%)28 (45.90%)Sarcomatoid transformation\< 0.001 absent1295 (95.22%)245 (18.92%)1050 (81.08%) present65 (4.78%)46 (70.77%)19 (29.23%)Tumor necrosis\< 0.001 absent940 (69.12%)158 (16.81%)782 (83.19%) present420 (30.88%)133 (31.67%)286 (68.33%)Lymphovascular invasion\< 0.001 absent1260 (92.65%)249 (19.76%)1011 (80.24%) present100 (7.35%)42 (42%)58 (58%)NLR\< 0.001 high317 (23.3%)166 (52.37%)151 (47.63%) low1043 (76.7%)125 (11.98%)918 (88.02%)PLR\< 0.001 high195 (14.3%)180 (92.31%)15 (7.69%) low1165 (85.7%)111 (9.53%)1054 (90.47%)^a^data are number of patients for those with HALP \< and ≥ 31.2

Association of HALP with patient outcomes {#Sec8}
-----------------------------------------

On univariate analysis, all included clinicopathologic features except for age (*P* = 0.287), gender (*P* = 0.226), histology subtype (*P* = 0.385) and American Society of Anesthesiologists grade (*P* = 0.964) were significantly related to survival outcomes (Table [3](#Tab3){ref-type="table"}). Anemia and hypoalbuminemia, high PLR and low HALP were all significantly associated with worse survival (Fig. [2](#Fig2){ref-type="fig"}). On multivariate analyses, prognostic factors for CSS with RCC were Fuhrman grade (HR 1.767, 95% CI 1.177--2.652, *P* = 0.006), T stage (3.890, 2.510--6.030, *P* \< 0.001), N stage (2.480, 1.526--4.032, *P* \< 0.001), M stage (4.728, 3.090--7.233, *P* \< 0.001) and HALP (1.838, 1.260--2.681, *P* = 0.002) (Table [3](#Tab3){ref-type="table"}).Table 3Univariate and multivariate analyses of factors associated with cancer-specific survival for RCC patientsVariableUnivariate analysis *P*Multivariate analysisHR (95% CI)*P*Age (\>65 vs ≤65)0.287Gender (female vs male)0.226Histology subtype (non-ccRCC vs ccRCC)0.385ASA grade (3 + 4 vs 1 + 2)0.964Fuhrman grade (3 + 4 vs 1 + 2)\< 0.0011.767 (1.177--2.652)0.006T stage (3 + 4 vs 1 + 2)\< 0.0013.890 (2.510--6.030)\< 0.001N status (positive/negative)\< 0.0012.480 (1.526--4.032)\< 0.001M status (positive vs negative)\< 0.0014.728 (3.090--7.233)\< 0.001Sarcomatous differentiation (present vs absent)\< 0.001Lymphovascular invasion (present vs absent)\< 0.001Necrosis (present vs absent)\< 0.001Hypoalbuminemia (present vs absent)\< 0.001Anemia (present vs absent)\< 0.001NLR (high vs low)\< 0.001PLR (high vs low)\< 0.001HALP (low vs high)\< 0.0011.838 (1.260--2.681)0.002Fig. 2Kaplan-Meier curves for cancer-specific survival in patients with RCC according to anemia (**a**), hypoalbuminemia (**b**), platelet-to-lymphocyte ratio (PLR)(**c**) and hemoglobin and albumin levels and lymphocyte and platelet counts (HALP) (**d**)

Nomogram of HALP-based risk model for RCC {#Sec9}
-----------------------------------------

We next used nomogram to predict 3- and 5-year CSS for individual patients. Independent prognostic factors in the multivariate analysis including Fuhrman grade, TNM status and HALP were included in the nomogram (Fig. [3](#Fig3){ref-type="fig"}). Similar to multivariate findings, with nomogram, high Fuhrman grade and advanced TNM status were associated with poor prognosis and high HALP with favorable prognosis.Fig. 3Nomogram for 3-year and 5-year survival with RCC

The calibration curves of the nomogram showed that the predictive probability of 3- and 5-year survival was closely related to the actual 3- and 5-year survival (Fig. [4](#Fig4){ref-type="fig"}). The C-index was 0.881 (95% CI: 0.853--0.909) by this nomogram compared with 0.846 (0.812--0.880) with the TNM staging system. Hence, the risk model including TNM stage, Fuhrman grade and HALP had better prognostic prediction accuracy than the only TNM system.Fig. 4Calibration curve for 3-year (**a**) and 5-year (**b**) survival

Discussion {#Sec10}
==========

In this study, we evaluated the prognostic significance of the novel index HALP combining hemoglobin and albumin levels and lymphocyte and platelet counts in RCC patients undergoing nephrectomy. HALP was closely associated with clinicopathologic features. Univariate and multivariate analyses demonstrated that HALP was an independent predictor of CSS for RCC patients undergoing nephrectomy. Furthermore, the nomogram based on HALP could predict prognosis more accurately than the TNM system.

There are several known predictive models of RCC such as TNM stage and the Stage, Size, Grading and Necrosis (SSIGN) model \[[@CR16]\]. Inflammatory and nutritional indicators based on hematologic parameters such as albumin and hemoglobin levels and lymphocyte, neutrophil and platelet counts were also associated with outcomes with RCC. Moreover, several indicators combined with hematologic parameters, including NLR, LMR, and PLR, were more accurate predictors \[[@CR6], [@CR9], [@CR10], [@CR12]\]. Recently, indicators combining albumin level with LMR or NLR were found significantly associated with outcomes \[[@CR17], [@CR18]\], which suggests better prediction of outcomes by combining inflammatory and nutritional indicators.

Accumulating evidence suggests the important role of the inflammatory response and nutritional status in cancer progression and metastasis. Overall, 30% of cancer patients were found with cancer-related anemia (CRA) at the time of diagnosis and CRA was associated with more advanced cancer stage \[[@CR19]\]. CRA is believed to be associated with chronic blood loss, iron deficiency, and vitamin B12 or folate nutritional deficiency. Meanwhile, imbalanced inflammation regulation, such as increased hepcidin and reactive oxygen species stress, in cancer patients is also responsible for CRA \[[@CR20]\]. Serum albumin is synthesized specially in the liver and known as a negative acute-phase protein. In addition, systemic factors such as inflammation and stress could affect serum albumin level. Therefore, decreased serum albumin level represents a malnutrition status and also a sustained systemic inflammation response. As important indicators of nutrition and inflammation, anemia and hypoalbuminemia are widely reported to be associated with worse outcomes in various cancers including RCC \[[@CR7], [@CR8]\]. Morgan et al. \[[@CR21]\] reported that for locoregional RCC patients undergoing nephrectomy, 25% of patients have anemia and 5.1% have hypoalbuminemia. The authors also found hypoalbuminemia (\< 35 g/L), unintentional preoperative weight loss ≥5% and preoperative BMI \< 18.5 kg/m2 as reflecting nutritional deficiency (ND) and that anemia and ND were independent predictors of overall mortality and disease-specific mortality. Preoperative hypoalbuminemia and anemia were also found to predict transfusion during radical nephrectomy for RCC \[[@CR5]\]. We observed 3.9% hypoalbuminemia and 19.6% anemia in our patients, which is consistent with previous study. On univariate analysis, both anemia and hypoalbuminemia were associated with worse survival.

Cancer-related inflammation is considered the seventh hallmark of cancer, playing a conflicting role in tumor initiation and progression in that both tumor-antagonizing and -promoting leukocytes can be found \[[@CR22]\]. Elevated neutrophil count is associated with cytokine secretion and contributes to tumor angiogenesis, promotion and metastasis. CD4+ and CD8+ T lymphocytes can enhance cancer immune-surveillance to inhibit tumour cell proliferation, invasion and metastasis \[[@CR23]\]. Increased neutrophil count and decreased lymphocyte count might be responsible for a weak and insufficient immune response to tumors and strongly associated with a poor survival in advanced cancer \[[@CR24], [@CR25]\].

Recent data implied that the activation of platelets is crucial for cancer progression by promoting angiogenesis, extracellular matrix degradation, and release of growth factors, which are essential components of tumor growth and metastatic \[[@CR26]\]. In addition, platelets adhering to tumor cells could secrete vascular endothelial growth factor(VEGF), which induces microvessel permeability, promotes extravasation of cancer cells, and induces neoangiogenesis \[[@CR27]\]. Platelet count was found a significant predictor of RCC-specific mortality \[[@CR28]\]. Recently, tumor-educated blood platelets (TEPs) were implicated as central players in the systemic and local responses to tumor growth. As well, the RNA profile in TEPs could provide a valuable platform for liquid biopsy \[[@CR29]\].

Systemic inflammation markers including NLR, LMR, and PLR have been found associated with survival in many solid tumors including RCC \[[@CR6], [@CR10], [@CR30], [@CR31]\]. Among those indicators, the finding of elevated NLR and PLR indicated increased neutrophil and platelet count and decreased lymphocyte count associated with worse outcomes. In our study, elevated NLR and PLR were associated with worse CSS on univariate analysis. However, on multivariate analyses, HALP rather than NLR and PLR remained an independent prognostic factor.

We used nomogram of independent prognostic factors found on multivariate analyses including HALP and evaluated their accuracy by calibration curves. The predictive accuracy was better with HALP than the TNM system. TNM stage may be an important factor in RCC, but other factors such as HALP could be included and improve the prediction of outcomes.

The major limitations of the present study are its retrospective nature and the single-center design. Additional large and prospective studies are needed to confirm these findings.

Conclusions {#Sec11}
===========

HALP was closely associated with clinicopathologic features of RCC patients undergoing nephrectomy and was an independent prognostic factor of CSS. A nomogram based on HALP could accurately predict prognosis with RCC. Preoperative HALP could be a novel indicator to evaluate the outcome for RCC patients after nephrectomy.

Additional file
===============

 {#Sec12}

Additional file 1:**Figure S1.** Cut-off values for neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). (TIFF 6359 kb)
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